TriaGen Wealth Management LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

TriaGen Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,334 shares of the biopharmaceutical company's stock, valued at approximately $1,402,000.

Other institutional investors also recently added to or reduced their stakes in the company. Global Assets Advisory LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth $339,594,000. Capital International Investors grew its stake in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock worth $868,757,000 after acquiring an additional 184,561 shares during the last quarter. TD Asset Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 162.9% in the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company's stock valued at $259,402,000 after buying an additional 166,998 shares in the last quarter. Finally, Swedbank AB acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $129,257,000. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares of the company's stock, valued at $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on REGN shares. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, September 23rd. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Argus increased their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a "buy" rating in a research report on Tuesday, June 25th. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a research note on Tuesday, July 23rd. Finally, Leerink Partners reiterated a "market perform" rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $1,116.00.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $7.55 during mid-day trading on Friday, reaching $990.68. 869,228 shares of the company's stock were exchanged, compared to its average volume of 496,271. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The stock's 50 day moving average is $1,109.58 and its 200 day moving average is $1,040.38. The company has a market cap of $109.16 billion, a price-to-earnings ratio of 29.27, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business's quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $8.79 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.